

PRESS RELEASE

BRAIN AG wins new long-term oriented investor by way of a capital increase

Zwingenberg, Germany
September 7, 2017

- **DAH Beteiligungs GmbH is new, long-term oriented investor of BRAIN AG supporting its growth strategy**
- **Capital increase by approximately 10% from Authorized Capital**
- **Proceeds from capital increase planned to be used for new acquisitions**

Zwingenberg, September 7, 2017: Today, the bioeconomy company BRAIN AG has successfully implemented a capital increase against contributions in cash, partially using its Authorized Capital. A total of 1,641,434 new registered no-par-value shares („New Shares“), corresponding to approximately 10% of the current share capital, was subscribed by one long-term oriented investor; the DAH Beteiligungs GmbH from Mannheim, Germany.

Dr Juergen Eck, CEO of BRAIN AG, says: „In our discussions with Daniel Hopp, the long-term nature and sustainability of his investment strategy was expressed. The investment of DAH Beteiligungs GmbH, coming on board about one and a half years after our successful IPO, is another important milestone in our growth strategy. We enable the biologisation of classical industrial processes and the corresponding development of new products. The aim is to reduce the dependency on valuable, limited raw materials in favour of more sustainability, nature and climate protection. Examples of this are our DOLCE program for the reduction of sugar consumption, our BioXtractor system for the extraction of precious

B·R·A·I·N

Biotechnology Research
And Information Network AG
Darmstädter Str. 34-36
64673 Zwingenberg
Germany

www.brain-biotech.de

Investor Relations Contact:

Dr Martin Langer
Executive Vice President
Corporate Development
Tel.: +49-6251-9331-16
Fax: +49-6251-9331-11
E-Mail: ir@brain-biotech.de

B•R•A•I•N

metals from waste streams, or the use of the greenhouse gas carbon dioxide as a raw material.“

Due to the capital increase, the company's share capital will increase from currently EUR 16,414,348.00 to EUR 18,055,782.00. The gross proceeds for BRAIN from this transaction will amount to approximately EUR 28 million.

Frank Goebel, CFO of BRAIN AG, says: „BRAIN has been pursuing a successful growth strategy for several years. The goal is, in addition to intensifying research collaborations with industrial partners, to develop and market our own biotechnological product candidates. In line with this strategy, the proceeds from the capital increase shall primarily be used to finance small and medium-sized acquisitions. Consequently, also our shareholders will benefit from our sustainable corporate strategy.”

Further information

Ad hoc release capital increase: <https://www.brain-biotech.de/en/investor-relations/financial-news/adhoc-news/>



About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this „Toolbox of Nature“ are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN's business model is based on two pillars – BioScience and BioIndustrial. The BioScience comprises its frequently exclusive collaboration business with industrial partners. BioIndustrial comprises the development and commercialization of BRAIN's own products and active product components. Further information is available at www.brain-biotech.de/en.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.